Fig. 2From: Primary tumor location predicts poor clinical outcome with cetuximab in RAS wild-type metastatic colorectal cancerKaplan–Meier estimates of (a) overall survival and (b) progression-free survival according to primary tumor location in RAS wild-type metastatic colorectal cancer patients (n = 170), and (c) overall survival and (d) progression-free survival in RAS and BRAF wild-type patients (n = 153)Back to article page